A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
A Multicenter Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan in Adult Participants With Primary IgA Nephropathy Who Have Completed Study CLNP023X2203 or CLNP023A2301
Sponsor: Novartis Pharmaceuticals
This PHASE3 trial investigates Primary IgA Nephropathy and is currently actively recruiting participants. Novartis Pharmaceuticals leads this study, which shows 25 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
25 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE3
-
Sep 2025 — Jan 2026 [monthly]
Recruiting PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE3
▶ Show 20 earlier versions
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE3
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE3
-
Jan 2025 — Apr 2025 [monthly]
Recruiting PHASE3
-
Oct 2024 — Jan 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE3
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Mar 2024 — May 2024 [monthly]
Recruiting PHASE3
-
Jan 2024 — Mar 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE3
-
Aug 2023 — Dec 2023 [monthly]
Recruiting PHASE3
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE3
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE3
-
Sep 2022 — Jun 2023 [monthly]
Recruiting PHASE3
-
Oct 2021 — Sep 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Aalborg, Denmark , Aarhus N, Denmark , Adelaide, Australia , Ankara, Turkey (Türkiye) , Antalya, Turkey (Türkiye) , Ashkelon, Israel , Aurora, United States , Baltimore, United States , Bangalore, India and 124 more locations